Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Neuroscience"

111 News Found

Marengo Asia launches functional neurosurgery centre, dance therapy for Parkinson’s care
Hospitals | April 16, 2026

Marengo Asia launches functional neurosurgery centre, dance therapy for Parkinson’s care

The hospital said the new centre will improve access to specialised interventions such as Deep Brain Stimulation


Beacon raises $132M+ to bring AI-driven sleep diagnostics to masses
Digitisation | April 10, 2026

Beacon raises $132M+ to bring AI-driven sleep diagnostics to masses

The device aims to bring precision neuroscience into clinical trials, accelerating drug development


FICCI Advantage Healthcare India 2026 honours Fortis Bannerghatta as top kidney transplant centre
Hospitals | April 02, 2026

FICCI Advantage Healthcare India 2026 honours Fortis Bannerghatta as top kidney transplant centre

A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India


Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal
News | April 01, 2026

Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal

The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions


Bristol Myers Squibb reports positive phase 4 data on Cobenfy for schizophrenia patients
News | March 31, 2026

Bristol Myers Squibb reports positive phase 4 data on Cobenfy for schizophrenia patients

The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks


Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal
News | March 28, 2026

Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal

Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones


AbbVie reports promising early results for novel obesity therapy ABBV-295
News | March 10, 2026

AbbVie reports promising early results for novel obesity therapy ABBV-295

ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks


AbbVie to invest $380 million in new North Chicago manufacturing facilities
News | February 24, 2026

AbbVie to invest $380 million in new North Chicago manufacturing facilities

Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade